

## Vivesto reports positive Cantrixil results in an animal hematological cancer model

Solna, Sweden, April 1, 2025 – Vivesto AB, an oncology-focused development company, today announced that positive preclinical efficacy data was obtained in an animal model of hematological cancer. The results support continued development of the candidate drug Cantrixil within this indication and are in line with previous positive preclinical data.

The experimental trial demonstrates, for the first time, that Cantrixil can reduce tumor growth and increase survival times in a well-established mouse model of hematological cancer. The treatment was well tolerated and safe.

“This is a significant milestone for the Cantrixil program. Obtaining positive efficacy data in vivo is not only important from a regulatory perspective, but it is also imperative in the development path towards showing potential benefits of Cantrixil in hematological cancer also in patients. Importantly, the treatment was also well tolerated. With these new results we are increasingly confident that Cantrixil can make a significant impact to patients and as well as build shareholder value,” said Erik Kinnman, CEO of Vivesto.

With the new positive data, Vivesto is continuing the planning of activities needed to bring Cantrixil into clinical trials and in parallel will investigate opportunities to partner the project in order to optimize the development program.

### For further information:

Erik Kinnman, Chief Executive Officer  
Phone: 018-50 54 40  
E-mail: IR@vivesto.com

### About Vivesto AB

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy. Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit [www.vivesto.com](http://www.vivesto.com) for more information about Vivesto.

### About Cantrixil

Cantrixil is a drug candidate in development for the treatment of advanced cancer. Cantrixil consists of the active molecule TRX-E-002-1, a selective third generation benzopyran and a potent tubulin polymerization inhibitor.

Vivesto has obtained positive results with Cantrixil, which has shown strong cytotoxic effects at low doses in cell lines derived from patients with untreated and relapse/refractory hematological cancers including leukemia, non-Hodgkin lymphoma and multiple myeloma. Positive in vitro preclinical data from so-called ADME studies (absorption, distribution, metabolism and excretion)

and secondary pharmacology studies presented in December 2023 confirm that Cantrixil has appropriate physicochemical properties and an acceptable safety profile with minimal "off-target" effects.

A new patent application covering the treatment of hematological cancer with Cantrixil has recently been filed, with the aim to strengthen the IP position. The company is focusing its efforts on developing Cantrixil for the treatment of hematological cancers with high unmet medical needs and significant commercial potential.

### Attachments

---

[Vivesto reports positive Cantrixil results in an animal hematological cancer model](#)